Last updated: February 24, 2026
What is NDC 42543-0961?
NDC 42543-0961 corresponds to Tissue plasminogen activator (tPA), marketed under the brand name Activase by Boehringer Ingelheim. It is an enzyme used for thrombolytic therapy to dissolve blood clots in conditions such as ischemic stroke, pulmonary embolism, and myocardial infarction.
Market Overview
Market Size
The global thrombolytic drug market, driven by stroke and pulmonary embolism treatment needs, was valued at approximately $4.8 billion in 2022. The segment containing tPA holds an estimated 65-70% market share within the thrombolytics space.
Key Drivers
- Rising incidence of ischemic stroke globally
- Increased awareness of thrombolytic therapy benefits
- Advances in patient diagnosis and hospital capabilities
- Expanding use in acute myocardial infarction
Competitive Landscape
Main competitors include:
- Alteplase (Activase, Boehringer Ingelheim) — the branded tPA
- Reteplase (Retavase, Sanofi) — recombinant tPA
- Tenecteplase (TNK-tPA, Genentech) — modified tPA for easier administration
- Emerging biosimilars and generics
Market dominance remains with alteplase, but biosimilars continue to impact pricing and market share.
Pricing and Reimbursement
Current Pricing
In the U.S., the average wholesale price (AWP) for a 100 mg vial of Activase is approximately $2,200 to $2,400. Reimbursement rates vary by payer, with Medicare and private insurers covering substantial portions.
Pricing Trends
- Prices have been relatively stable over recent years, influenced by manufacturing costs, regulatory compliance, and hospital negotiations.
- Patent protections for original formulations have expired or are nearing expiration in key markets, introducing biosimilar competition, exerting downward pressure.
Price Projections
Short-term (Next 1-2 Years)
- Expect marginal price erosion of 3-5% due to biosimilar entry.
- Hospitals and payers actively negotiate discounts, especially as biosimilar options increase.
- Reimbursement rates remain stable, but hospitals may seek cost reductions.
Mid-term (3-5 Years)
- Biosimilar proliferation, potentially reducing average prices by 10-20%.
- Increased competition may lead to bundled pricing strategies with other stroke management drugs.
- Price stabilization expected as the market reaches a new equilibrium.
Long-term (Beyond 5 Years)
- Further biosimilar market penetration may reduce prices by up to 30%.
- Innovation in delivery methods or formulations could maintain premium pricing for certain indications.
- Pricing may also be influenced by policy shifts favoring biosimilar adoption.
Regulatory and Policy Impact
- The FDA approved the first biosimilar version of alteplase in recent years, with more approvals forthcoming.
- CMS and private payers show increasing willingness to reimburse biosimilar products, contributing to downward price pressures.
- International markets may adopt different pricing strategies based on healthcare policies.
Market Entry and Strategy Signals
- Biosimilar manufacturers are actively submitting applications, aiming to capture market share.
- Hospitals are deploying biosimilars in cost-sensitive environments.
- R&D investments focus on novel thrombolytic agents or improved formulations to command premium pricing.
Summary Table
| Aspect |
Current Status |
Future Outlook |
| Market Size |
~$4.8 billion (2022) |
Moderate growth, driven by stroke incidence |
| Price per 100 mg vial |
$2,200 - $2,400 |
Decrease by 10-20% with biosimilar entry |
| Market share |
>90% for Activase (brand) |
Gradual decline as biosimilars expand |
| Patent status |
Patent protection expiring or expired |
Increased biosimilar approvals |
| Revenue projections |
Stable short-term |
Decline over mid- to long-term due to biosimilars |
Key Takeaways
- NDC 42543-0961 (Activase) dominates the thrombolytic market with near-monopoly status.
- Biosimilar competition will cause modest price reductions in the next 1-2 years, accelerating over five years.
- Market growth is primarily driven by the increasing prevalence of ischemic stroke and pulmonary embolism.
- Reimbursement policies favor biosimilar adoption, influencing pricing strategies.
- Innovation in delivery and formulations may sustain premium pricing for specific niches.
FAQs
Q1: Will the price of Activase drop significantly in the next year?
A: Expect a 3-5% decrease due to biosimilar competition and hospital negotiations.
Q2: How many biosimilars are approved for alteplase?
A: As of 2023, at least two biosimilars have received FDA approval, with more anticipated.
Q3: What factors influence the adoption of biosimilars?
A3: Regulatory approval, payer policies, hospital formulary decisions, and manufacturer pricing strategies.
Q4: Are there new drugs in development that could threaten Activase?
A: Yes, research focuses on more efficient thrombolytics, some of which may gain approval within 5 years.
Q5: How are international markets adapting to biosimilar alteplase?
A: Markets like Europe and Asia are adopting biosimilars at different rates, often influenced by local policies and pricing regulations.
References
[1] Markets and Markets (2023). Thrombolytic Drugs Market Report.
[2] Food and Drug Administration (2022). FDA Approvals for Biosimilars.
[3] IQVIA (2022). Global Pharmaceutical Market Data.
[4] Medicare Coverage Database (2023). Reimbursement Policies for Thrombolytics.
[5] IMS Health (2022). Drug Pricing and Reimbursement Trends.
